CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, ANALYSIS

Regional Analysis

Global Clostridioides Difficile Infection Treatment Market - Regional Analysis

Among all regions, North America is expected to dominate the market over the forecast period. This is attributed due to North America holding 39.6% market share in the year 2023 and market players operating in the region focusing on carrying out research and development activities for launching new therapy for the treatment of clostridioides difficile infection. For instance, in September 2022, Seres Therapeutics, Inc., a biotechnology company, announced the completion of the rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rClostridioides Difficile Infection). Due to SER-109's U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation, the Biologics License Application (BLA) may receive priority review. If granted, Seres estimates SER-109's potential approval and release in the first half of 2023, with SER-109 possibly becoming the first oral microbiome treatment ever to receive the U.S. Food and Drug Administration (FDA) approval.

Europe is expected to be the second-largest region over the forecast period, due to increasing clinical trials for treating the clostridioides difficile infection. For instance, in March 2022, Lausanne University Hospital, a University hospital in Lausanne, Switzerland initiated a clinical trial “to evaluate the efficacy of fecal microbiota transplantation (FMT) versus the pragmatic use of the standard of care treatment (either vancomycin or fidaxomicin) in severe and non-severe first recurrence of Clostridioides difficile infection (rClostridioides Difficile Infection)”. The fecal microbiota transplantation versus vancomycin or fidaxomicin in clostridioides difficile infection study is currently in the phase 3 trial. The study is estimated to be completed by December 2025.